Kolon Life Science Inc. (KOSDAQ: 102940)

South Korea flag South Korea · Delayed Price · Currency is KRW
18,510
+160 (0.87%)
Sep 11, 2024, 11:03 AM KST
-35.62%
Market Cap 229.09B
Revenue (ttm) 140.27B
Net Income (ttm) -84.29B
Shares Out 12.42M
EPS (ttm) -7,367.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,191
Open 18,350
Previous Close 18,350
Day's Range 18,350 - 18,790
52-Week Range 17,330 - 31,000
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 14, 2024

About Kolon Life Science

Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, ... [Read more]

Industry Medicinal Chemicals and Botanical Products
Founded 2000
Employees 421
Stock Exchange KOSDAQ
Ticker Symbol 102940
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.